Abstract:Hepatobiliary disorders are among the most common extraintestinal manifestations in inflammatory bowel diseases (IBD), both in Crohn's disease and ulcerative colitis (UC), and therefore represent a diagnostic challenge. Immune-mediated conditions include primary sclerosing cholangitis (PSC) as the main form, variant forms of PSC (namely small-duct PSC, PSC-autoimmune hepatitis overlap syndrome and IgG4-related sclerosing cholangitis) and granulomatous hepatitis. PSC is by far the most common, presenting in up to 8% of IBD patients, more frequently in UC. Several genetic foci have been identified, but environmental factors are preponderant on disease pathogenesis. The course of the two diseases is typically independent. PSC diagnosis is based mostly on typical radiological findings and exclusion of secondary cholangiopathies. Risk of cholangiocarcinoma is significantly increased in PSC, as well as the risk of colorectal cancer in patients with PSC and IBD-related colitis. No disease-modifying drugs are approved to date. Thus, PSC management is directed against symptoms and complications and includes medical therapies for pruritus, endoscopic treatment of biliary stenosis and liver transplant for end-stage liver disease. Other non-immune-mediated hepatobiliary disorders are gallstone disease, whose incidence is higher in IBD and reported in up to one third of IBD patients, non-alcoholic fatty liver disease, pyogenic liver abscess and portal vein thrombosis. Drug-induced liver injury (DILI) is an important issue in IBD, since most IBD therapies may cause liver toxicity; however, the incidence of serious adverse events is low. Thiopurines and methotrexate are the most associated with DILI, while the risk related to anti-tumor necrosis factor-α and anti-integrins is low. Data on hepatotoxicity of newer drugs approved for IBD, like anti-interleukin 12/23 and tofacitinib, are still scarce, but the evidence from other rheumatic diseases is reassuring. Hepatitis B reactivation during immunosuppressive therapy is a major concern in IBD, and adequate screening and vaccination is warranted. On the other hand, hepatitis C reactivation does not seem to be a real risk, and hepatitis C antiviral treatment does not influence IBD natural history. The approach to an IBD patient with abnormal liver function tests is complex due to the wide range of differential diagnosis, but it is of paramount importance to make a quick and accurate diagnosis, as it may influence the therapeutic management.

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Dissecting the molecular pathophysiology of drug-induced liver injury

Role of Gut Microecology in the Pathogenesis of Drug-Induced Liver Injury and Emerging Therapeutic Strategies

Idiosyncratic drug-induced liver injury: an overview

Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes

Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury

Drug‐Induced Liver Injury: The Role of Drug Metabolism and Transport

Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review

Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury

Mechanism of drug-induced liver injury and hepatoprotective effects of natural drugs

Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury

Liver manifestations and complications in inflammatory bowel disease: A review

Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

Drug-induced liver injury: a comprehensive review

A unusual presentation of liver failure caused by Ibuprofen-sustained release capsules: A case report

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques

Idiosyncratic drug-induced liver injury: an update on the 2007 overview

Contribution of gut microbiota to drug-induced liver injury

Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury